Skip to content

Author

B. von Tresckow

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Disease burden at the time of BCMA-directed chimeric antigen receptor (CAR) T-cell infusion is a key determinant of outcome in relapsed or refractory multiple myeloma (RRMM). Bridging therapy is frequently administered between leukapheresis and infusion to prevent disease progression, yet its clinical impact remains un...

M. Wesener, U. Demel, T. Pabst et al. · 0 citations
Open access Sep 2026

Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis.

Lonca demonstrated a favorable safety profile with moderate efficacy in heavily pretreated patients, while enabling timely access to subsequent therapy, efficacy in earlier lines with combination partners may further increase response rates and durability of response.

E. Shumilov, Lina J. Kolloch, Philipp Faustmann et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.